Abstract
Introduction As the SARS-CoV-2 pandemic disproportionately affects older adults, future pandemic vaccine response will rely on existing adult immunization infrastructures.
Methods We evaluated the 2018 WHO/UNICEF Joint Reporting Form on Immunization for country reports on adult immunization programs. We described countries with programs and used multivariable regression to identify independent factors associated with having them.
Results Of 194 WHO Member States, 120 (62%) reported having any adult vaccination program. The Americas and Europe had the most adult immunization programs, most commonly Hepatitis B and influenza vaccines (>45% and >90% of countries). Africa and South-East Asia had the fewest adult immunization programs, with <11% of countries reporting any adult immunization programs for influenza or hepatitis vaccines, and none for pneumococcal vaccines. In bivariate analyses, high- or upper-middle income, introduction of new or underused vaccines, having achieved pediatric vaccine coverage goals, and meeting National Immunization Technical Advisory Groups basic functional indicators were significantly associated (p<0.001) with having any adult immunization programs. In multivariable analyses, the factor most strongly associated with adult immunization programs was country income, with high- or upper-middle income countries significantly more likely to report having a program (aOR 19.3, 95% CI 6.5, 57.7).
Discussion That 38% of countries lack functional platforms for adult immunization has major implications for future SARS-CoV-2 vaccine deployment. Systems for vaccine storage and handling, delivery, and waste management for adult immunization do not exist in much of the world. Developing countries should strengthen immunization programs to reach adults with SARS-CoV-2 vaccines when they become available.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
There was no specific funding for this study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
None needed, we analyzed publicly available dataset with country-level data.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Added a European Region-specific analysis and minor changes of format, diction, and grammar for sense.
Data Availability
All data are available from the references provided.
http://www.who.int/immunization/monitoring_surveillance/routine/reporting/reporting/en/
https://datahelpdesk.worldbank.org/knowledgebase/articles/906519
https://databank.worldbank.org/reports.aspx?source=2&series=SH.XPD.GHED.PC.CD
